Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wenning, GK; Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society.
Placebo-controlled trial of amantadine in multiple-system atrophy.
Clin Neuropharmacol. 2005; 28(5):225-227
Doi: 10.1097/01.wnf.0000183240.47960.f0
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Bonelli Raphael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: Multiple-system atrophy (MSA) often presents as atypical parkinsonian syndrome with rapid progression and poor response to levodopa. Reports on the open-label use of amantadine in MSA suggest variable antiparkinsonian efficacy. The authors therefore conducted a double-blind, placebo-controlled crossover trial of amantadine in MSA patients. METHODS: Eight patients were enrolled in this study. They received either amantadine 200 mg twice daily or placebo for 3 weeks, followed by a 1-week washout and the alternate treatment of 3 weeks. Antiparkinsonian effects were evaluated using the Unified Parkinson's Disease Rating Scale part II (UPDRS-II, activities of daily living) and UPDRS-III (motor examination) before and at the end of each treatment phase. Timed tests were also performed according to the CAPIT protocol. RESULTS: There was a trend toward reduction of UPDRS-III scores during amantadine treatment (P = 0.058). Delta values of the treatment arm were higher than those of the placebo arm. However, this difference (-2.25 pt; 95% CI, -6.7-2.2) failed to reach significance. Reduction of UPDRS-III subscores for akinesia, rigidity, tremor, postural instability, and gait disorder failed to reach significance too. The hand-arm movement test revealed nonsignificant improvement in the amantadine arm. CONCLUSION: This study suggests that amantadine fails to provide clinically significant antiparkinsonian benefit to patients with MSA. The authors cannot exclude mild effects due to the limited sample size.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Amantadine - adverse effects
- Antiparkinson Agents - adverse effects
- Cross-Over Studies - adverse effects
- Double-Blind Method - adverse effects
- Female - adverse effects
- Humans - adverse effects
- Male - adverse effects
- Middle Aged - adverse effects
- Multiple System Atrophy - drug therapy
- Patient Compliance - drug therapy
- Treatment Outcome - drug therapy
- Find related publications in this database (Keywords)
- multiple-system
- atrophy
- amantadine
- crossover trial